Abstract

Mini Review

Current Practices for Severe Alpha-1 Antitrypsin Deficiency Associated COPD and Emphysema

MJ Nicholson* and M Seigo

Published: 26 July, 2024 | Volume 8 - Issue 2 | Pages: 044-047

Alpha-1 antitrypsin deficiency is a genetic disorder that can lead to chronic obstructive pulmonary disease and emphysema. Although it is the most well-studied genetic risk factor for emphysema, data is still scarce. Traditionally, medical therapy is similar to standard chronic obstructive pulmonary disease patients. Over the past several decades, enzyme augmentation therapy has emerged as a highly utilized alpha-1 antitrypsin-specific therapy. It has become the standard of care for severe alpha-1 antitrypsin deficiency despite unclear effects on a multitude of clinical outcomes. Significant data supports interventional therapies, including lung volume reduction surgery and bronchoscopic lung volume reduction, for chronic obstructive pulmonary disease patients without alpha-1 antitrypsin deficiency. These interventions have less robust data in the treatment of alpha-1 antitrypsin-induced chronic obstructive pulmonary disease. This review will explore the data regarding various treatment options for severe alpha-1 antitrypsin deficiency associated with chronic obstructive pulmonary disease and emphysema.

Read Full Article HTML DOI: 10.29328/journal.jprr.1001058 Cite this Article Read Full Article PDF

References

  1. Strnad P, McElvaney NG, Lomas DA. Alpha1-Antitrypsin Deficiency. N Engl J Med. 2020;382(15):1443-1455. Available from: https://doi.org/10.1056/nejmra1910234
  2. Stoller JK, Aboussouan LS. Α1-antitrypsin deficiency. Lancet. 2005;365(9478):2225-2236. Available from: https://doi.org/10.1016/s0140-6736(05)66781-5
  3. Ogushi FG, Fells GA, Hubbard RC, Straus SD, Crystal RG. Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase. J Clin Invest. 1987;80(5):1366-1374. Available from: https://doi.org/10.1172/JCI113214
  4. Lieberman J, Winter B, Sastre A. Alpha1-antitrypsin Pi-types in 965 COPD patients. Chest. 1986;89(3):370-373. Available from: https://doi.org/10.1378/chest.89.3.370
  5. Stoller JK. Detecting alpha-1 antitrypsin deficiency. Ann Am Thorac Soc. 2016;13(Suppl 4). Available from: https://doi.org/10.1513/AnnalsATS.201506-349KV
  6. Campos MA, Wanner A, Zhang G, Sandhaus RA. Trends in the diagnosis of symptomatic patients with α1-antitrypsin deficiency between 1968 and 2003. Chest. 2005;128(3):1179-1186. Available from: https://doi.org/10.1378/chest.128.3.1179
  7. Greulich T, Ottaviani S, Bals R, Lepper PM, Vogelmeier C, Luisetti M, et al. α1-Antitrypsin deficiency—diagnostic testing and disease awareness in Germany and Italy. Respir Med. 2013;107(10):1400-1408. Available from: https://doi.org/10.1016/j.rmed.2013.04.023
  8. Stoller JK, Sandhaus RA, Turino G, Dickson R, Rodgers K, et al. Delay in diagnosis of alpha-1 antitrypsin deficiency: a continuing problem. Chest. 2005;128(4):1989-1994. Available from: https://doi.org/10.1378/chest.128.4.1989
  9. Tejwani V, Nowacki AS, Fye E, Sanders C, Stoller JK. The impact of delayed diagnosis of alpha-1 antitrypsin deficiency: the association between diagnostic delay and worsened clinical status. Respir Care. 2019;64(7):915-922. Available from: https://doi.org/10.4187/respcare.06555
  10. World Health Organization. Alpha-1 antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ. 1997;75(5):397-415. Available from: https://www.proquest.com/openview/cbc69103dbd276091b9d33887c12ff6d/1?pq-origsite=gscholar&cbl=38034
  11. Parr DG, Stoel BC, Stolk J, Stockley RA. Pattern of emphysema distribution in alpha1-antitrypsin deficiency influences lung function impairment. Am J Respir Crit Care Med. 2004;170(9):1172-1178. Available from: https://doi.org/10.1164/rccm.200406-761OC
  12. McElvaney NG. Diagnosing α1-antitrypsin deficiency: How to improve the current algorithm. Eur Respir Rev. 2015;24(135):52-57. Available from: https://doi.org/10.1183/09059180.10010814
  13. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818-900. Available from: https://doi.org/10.1164/rccm.168.7.818
  14. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994;272(19):1497-1505. Available from: https://pubmed.ncbi.nlm.nih.gov/7966841/
  15. Miravitlles M, Dirksen A, Ferrarotti I, Koblizek V, Lange P, Mahadeva R, et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency. Eur Respir J. 2017;50(5):1700610. Available from: https://doi.org/10.1183/13993003.00610-2017
  16. Hosenpud JD, Novick RJ, Breen TJ, Keck B, Daily P. The Registry of the International Society for Heart and Lung Transplantation: twelfth official report--1995. J Heart Lung Transplant. 1995;14(5):805-815. Available from: https://pubmed.ncbi.nlm.nih.gov/8800714/
  17. Levine SM, Anzueto A, Peters JI, Cronin T, Sako EY, Jenkinson SG, et alL. Medium term functional results of single-lung transplantation for end stage obstructive lung disease. Am J Respir Crit Care Med 1994;150:398–402. Available from: https://doi.org/10.1164/ajrccm.150.2.8049821
  18. Trulock E. Lung transplantation for alpha-1 antitrypsin deficiency emphysema. Chest 1996;110:248–294. Available from: https://doi.org/10.1378/chest.110.6_supplement.284s
  19. Tanash HA, Riise GC, Hansson L, Nilsson PM, Piitulainen E. Survival benefit of lung transplantation in individuals with severe α1-anti-trypsin deficiency (PiZZ) and emphysema. J Heart Lung Transplant. 2011;30(12):1342-7. Available from: https://doi.org/10.1016/j.healun.2011.07.003
  20. Stone HM, Edgar RG, Thompson RD, Stockley RA. Lung Transplantation in Alpha-1-Antitrypsin Deficiency. COPD. 2016;13(2):146-52. Available from: https://doi.org/10.3109/15412555.2015.1048850
  21. Morer L, Choudat L, Dauriat G, Durand F, Cazals-Hatem D, Thabut G, et al. Liver Involvement in Patients With Pi ZZ‐Emphysema, Candidates for Lung Transplantation. Am J Transplant. 2017;17(5):1389-1395. Available from: https://doi.org/10.1111/ajt.14152
  22. Smith DJ, Ellis PR, Turner AM. Exacerbations of lung disease in alpha-1 antitrypsin deficiency. Chron Obstruct Pulmon Dis. 2021;8(1):162-176. Available from: https://doi.org/10.15326/jcopdf.2020.0173
  23. Modrykamien A, Stoller JK. Alpha-1 antitrypsin (AAT) deficiency - what are the treatment options?. Expert Opin Pharmacother. 2009;10(16):2653-2661. Available from: https://doi.org/10.1517/14656560903300111
  24. Chapman KR, Burdon JG, Piitulainen E, Sandhaus RA, Seersholm N, Stocks JM, et al.; RAPID Trial Study Group. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(9991):360-368. Available from: https://doi.org/10.1016/s0140-6736(15)60860-1
  25. McElvaney NG, Burdon J, Holmes M, Glanville A, Wark PA, Thompson PJ, et al.; RAPID Extension Trial Group. Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). Lancet Respir Med. 2017;5(1):51-60. Available from: https://doi.org/10.1016/s2213-2600(16)30430-1
  26. Dowson LJ, Guest PJ, Hill SL, Holder RL, Stockley RA. High-resolution computed tomography scanning in alpha1-antitrypsin deficiency: relationship to lung function and health status. Eur Respir J. 2001;17(6):1097-1104. Available from: https://doi.org/10.1183/09031936.01.00056501
  27. Miravitlles M, Anzueto A, Barrecheguren M. Nine controversial questions about augmentation therapy for alpha-1 antitrypsin deficiency: A viewpoint. Eur Respir Rev. 2023;32(170):230170. Available from: https://doi.org/10.1183/16000617.0170-2023
  28. Gelb AF, McKenna RJ, Brenner M, Fischel R, Zamel N. Lung function after bilateral lower lobe lung volume reduction surgery for alpha1-antitrypsin emphysema. Eur Respir J. 1999;14(4):928-933. Available from: https://erj.ersjournals.com/content/14/4/928.short
  29. Tutic M, Bloch KE, Lardinois D, Brack T, Russi EW, Weder W. Long-term results after lung volume reduction surgery in patients with alpha1-antitrypsin deficiency. J Thorac Cardiovasc Surg. 2004;128(3):408-413. Available from: https://doi.org/10.1016/j.jtcvs.2004.03.040
  30. Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003;348(21):2059-2073. Available from: https://doi.org/10.1056/nejmoa030287
  31. Stoller JK, Gildea TR, Ries AL, Meli YM, Karafa MT; National Emphysema Treatment Trial Research Group. Lung volume reduction surgery in patients with emphysema and alpha-1 antitrypsin deficiency. Ann Thorac Surg. 2007 Jan;83(1):241-251. Available from: https://doi.org/10.1016/j.athoracsur.2006.07.080
  32. Rathinam S, Davies RJO, Ali J, Phillips J, Leonard C, McStay R, et al. The role of the emphysema multidisciplinary team in a successful lung volume reduction surgery programme. Eur J Cardiothorac Surg. 2014;46(6):1021-1026; discussion 1026. Available from: https://doi.org/10.1093/ejcts/ezu129
  33. Clark SJ, Oey I, Steiner M, Spyt T, Morgan MD, Waller DA. Surgical approaches for lung volume reduction in emphysema. Clin Med (Lond). 2014;14(2):122-127. Available from: https://doi.org/10.7861/clinmedicine.14-2-122
  34. Sandhaus RA, Turino G, Brantly ML, Campos M, Cross CE, Goodman K, et al. The diagnosis and management of alpha-1 antitrypsin deficiency in the adult. Chronic Obstr Pulm Dis. 2016;3(3):668-682. Available from: https://doi.org/10.15326/jcopdf.3.3.2015.0182
  35. Criner GJ, Sue R, Wright S, Dransfield M, Rivas-Perez H, Wiese T, et al. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE). Am J Respir Crit Care Med. 2018;198(9):1151-1164. Available from: https://doi.org/10.1164/rccm.201803-0549OC
  36. Criner GJ, Delage A, Voelker K, Hogarth DK, Majid A, Zgoda M, et al. Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System (EMPROVE). Am J Respir Crit Care Med. 2019;200(11):1354-1362. Available from: https://doi.org/10.1164/rccm.201902-0383OC
  37. Hartman JE, Welling JBA, Klooster K, Carpaij OASW, Augustijn SWS, Slebos DJ, et al. Survival in COPD patients treated with bronchoscopic lung volume reduction. Respir Med. 2022;196:106825. Available from: https://doi.org/10.1016/j.rmed.2022.106825
  38. Everaerts S, Hartman JE, Van Dijk M, Koster TD, Slebos DJ, Klooster K, et al. Bronchoscopic Lung Volume Reduction in Patients with Emphysema due to Alpha-1 Antitrypsin Deficiency. Respiration. 2023;102(2):134-142. Available from: https://doi.org/10.1159/000528182
  39. Hogarth DK, Delage A, Zgoda MA, Nsiah-Dosu S, Himes D, Reed MF. Efficacy and safety of the Spiration Valve System™ for the treatment of severe emphysema in patients with alpha-1 antitrypsin deficiency (EMPROVE). Respir Med. 2024;224:107565. Available from: https://doi.org/10.1016/j.rmed.2024.107565

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?